Stable Peptide of Endogenous Opioid Enkephalin Precursor, Breast Cancer Risk

Share this content:
Low fasting plasma concentration of the opioid precursor peptide pro-enkephalins has been linked to an increased risk of future breast cancer.
Low fasting plasma concentration of the opioid precursor peptide pro-enkephalins has been linked to an increased risk of future breast cancer.

Low fasting plasma concentration of the opioid precursor peptide pro-enkephalins has been linked to an increased risk of future breast cancer in middle-aged and postmenopausal women, according to a recent study published online ahead of print in the Journal of Clinical Oncology.

Researchers hypothesized that plasma levels of ENKs are predictive of long-term breast cancer risk. In experimental studies, ENKs and related opioids were implicated as negative regulators of breast cancer development through enhancing immune-mediated tumoral defense and by directly inhibiting cancer cells.

The study's purposes were to measure pro-ENK, a surrogate for mature ENK, and assess its predictive value regarding development of breast cancer in a population of middle-aged women and in an independent study population.

RELATED: For Breast Cancer, Docetaxel Improves Progression-Free Survival

Pro-ENK was related in fasting plasma samples from 1,929 healthy women (mean age, 57.6 ± 5.9 years) of the Malmӧ Diet and Cancer study to breast cancer incidence (n = 123) during a median follow-up of 14.7 years. For replication, pro-ENK was related to risk of breast cancer (n = 130) in an older independent sample from the Malmӧ Preventive Project, which consisted of 1,569 women (mean age, 70.0 ± 4.4 years).

In the Malmӧ Diet and Cancer study, Pro-ENK was inversely related to the risk of breast cancer incidence. The results were replicated in the Malmӧ Preventive Project.

Reference

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs